Literature DB >> 23041775

Is it possible to achieve a target of zero central line associated bloodstream infections?

Leon J Worth1, Mary-Louise McLaws.   

Abstract

PURPOSE OF REVIEW: Central venous catheter (CVC)-associated bloodstream infections (CLABSIs) result in poorer patient outcomes and increased healthcare costs. Reduced reimbursement for CLABSI events is now provided for hospitalized patients in the United States. Although a zero target is proposed, the feasibility has not been evaluated. The objective of this review is to identify factors contributing to CLABSI and determine whether current evidence supports attainment of a zero infection rate. RECENT
FINDINGS: Limitations of current surveillance methods and reporting of aggregate data impact on achieving target CLABSI rates. Standard prevention practices, including physician and patient preparation (e.g. hand hygiene), are frequently incorporated into bundles of care. CVC dwell time has been identified as means of risk stratification. Additional strategies (e.g. chlorhexidine-impregnated dressings, antimicrobial-coated devices) may be better used in patients with expected long dwell times. Non-ICU populations are increasingly targeted with prevention strategies, but expected rates of infection have not been proposed.
SUMMARY: A zero CLABSI rate should be the target only for ICU populations having CVCs with a dwell time of 1-9 days following aseptic insertion. Additional measures should be reserved for patients with expected longer dwell time. Refinement and validation of surveillance methodology is required before target CLABSI rates can be proposed for non-ICU populations.

Entities:  

Mesh:

Year:  2012        PMID: 23041775     DOI: 10.1097/QCO.0b013e32835a0d1a

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  8 in total

1.  Reduction of central venous line-associated bloodstream infection rates by using a chlorhexidine-containing dressing.

Authors:  S Scheithauer; K Lewalter; J Schröder; A Koch; H Häfner; V Krizanovic; K Nowicki; R-D Hilgers; S W Lemmen
Journal:  Infection       Date:  2013-08-09       Impact factor: 3.553

Review 2.  Infection Risk in Sterile Operative Procedures.

Authors:  Evelina Tacconelli; Niklas F Müller; Sebastian Lemmen; Nico T Mutters; Stefan Hagel; Elisabeth Meyer
Journal:  Dtsch Arztebl Int       Date:  2016-04-22       Impact factor: 5.594

3.  A quality assurance investigation of CLABSI events: are there exceptions to never?

Authors:  Samantha Strickler; Rohit R Gupta; John T Doucette; Roopa Kohli-Seth
Journal:  J Infect Prev       Date:  2017-07-28

4.  Chlorhexidine gluconate transparent dressing does not decrease central line-associated bloodstream infection in critically ill patients: A randomized controlled trial.

Authors:  Kunrong Yu; Meishan Lu; Yanling Meng; Yanwei Zhao; Zheng Li
Journal:  Int J Nurs Pract       Date:  2019-10-20       Impact factor: 2.226

5.  Central line associated blood stream infection rate after intervention and comparing outcome with national healthcare safety network and international nosocomial infection control consortium data.

Authors:  Sz Bukhari; A Banjar; Ss Baghdadi; Ba Baltow; Am Ashshi; Wm Hussain
Journal:  Ann Med Health Sci Res       Date:  2014-09

6.  A comprehension scale for central-line associated bloodstream infection: Results of a preliminary survey and factor analysis.

Authors:  Sushant Govindan; Katherine Prenovost; Vineet Chopra; Theodore J Iwashyna
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

7.  Central line-associated bloodstream infections in Australian ICUs: evaluating modifiable and non-modifiable risks in Victorian healthcare facilities.

Authors:  T Spelman; D V Pilcher; A C Cheng; A L Bull; M J Richards; L J Worth
Journal:  Epidemiol Infect       Date:  2017-09-04       Impact factor: 4.434

8.  Ethanol locks for the prevention of catheter-related bloodstream infection: a meta-analysis of randomized control trials.

Authors:  Peng Zhang; Jun-Hao Lei; Xin-Jun Su; Xing-Huan Wang
Journal:  BMC Anesthesiol       Date:  2018-07-24       Impact factor: 2.217

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.